These findings provide evidence for the potential antitumor effects of ERβ in colorectal cancer (CRC), suggesting that the expression levels of ERα and ERβ could serve as biomarkers for assessing the risk and prognosis of CRC. The gene discussed is ESR1; the disease is colorectal carcinoma.